Economic Modeling For Jordan Of The Cost-Efficiency And Associated Expanded Treatment Access Of Conversion To Rituximab Biosimilar From Reference Rituximab

By
Hala Hisham Halawah

Supervisor
Dr. Nimer Alkhatib

Al-Zaytoonah University of Jordan, 2022

Abstract

Background: Rituximab biosimilars are approved to have comparable efficacy and safety profiles with rituximab originators in the treatment of the approved indications, which enables countries like Jordan to use them as cost-efficient alternatives to the originator rituximab.

Objectives: This study estimated the annual cost of rituximab originator against biosimilars approved in Jordan in the approved indications. Also, the study accounted for the head-to-head cost comparisons, changes in patient access, and relative spending on rituximab options, in the case of switching between alternatives.

Method: the budget impact analysis was constructed to estimate the cost implications of the introduction of Mabthera®, and the biosimilars Truxima®, Rixathon®, and Tromax® into the Jordanian market using the available doses.

Results: Rixathon® was associated with the lowest yearly cost in the approved indications; coupled with the highest percentages of patient access.

Conclusion: Generally, rituximab biosimilars are associated with cost savings over the rituximab originator.

Keywords: Biosimilars, Budget Impact Analysis, Economic Evaluation, Jordan, Rituximab.